Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30602795 | 1.00 | FOLH1 (0.51) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL29373136 | 1.00 | FOLH1 (0.51) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL30428059 | 1.00 | FOLH1 (0.51) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL30300584 | 1.00 | FOLH1 (0.51) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL23230145 | 0.98 | FOLH1 (0.50) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL29563714 | 0.94 | FOLH1 (0.57) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL1711242 | 0.94 | FOLH1 (0.57) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL29368554 | 0.94 | FOLH1 (0.57) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL29511099 | 0.94 | FOLH1 (0.57) | FOLH1NOD1CPB2SLC6A5GSR | |
| SCHEMBL1711244 | 0.94 | FOLH1 (0.57) | FOLH1NOD1CPB2SLC6A5GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250020668-A1 | CANCER LESION TISSUE EVALUATION FOR OPTIMIZING EFFECT OF BORON NEUTRON CAPTURE THERAPY | 3-D MATRIX, LTD. (JP) | 2025-01-16 | — | — | US | disclosed |
| EP-3754336-B1 | CANCER LESION TISSUE EVALUATION FOR OPTIMIZING EFFECT OF BORON NEUTRON CAPTURE THERAPY | 3 D MATRIX LTD (JP) | 2024-01-17 | — | — | EP | disclosed |
| US-20210106506-A1 | METHODS FOR COSMETIC SKIN REMODELING | ELC MANAGEMENT LLC | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106506-A1 | METHODS FOR COSMETIC SKIN REMODELING | CUTA, PLOD3, KRT18 | FOLH1 4678/4885NOD1 4786/4885CPB2 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.